1. Home
  2. AMPY vs MGNX Comparison

AMPY vs MGNX Comparison

Compare AMPY & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amplify Energy Corp.

AMPY

Amplify Energy Corp.

HOLD

Current Price

$3.96

Market Cap

215.9M

Sector

Energy

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$3.69

Market Cap

220.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMPY
MGNX
Founded
2011
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
215.9M
220.6M
IPO Year
2011
2013

Fundamental Metrics

Financial Performance
Metric
AMPY
MGNX
Price
$3.96
$3.69
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$5.00
AVG Volume (30 Days)
857.7K
1.2M
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
232.26
N/A
EPS
N/A
N/A
Revenue
$208,637,000.00
$149,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$23.83
$3.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.41
$1.30
52 Week High
$6.79
$5.08

Technical Indicators

Market Signals
Indicator
AMPY
MGNX
Relative Strength Index (RSI) 41.82 36.46
Support Level $3.86 $1.49
Resistance Level $4.23 $3.88
Average True Range (ATR) 0.15 0.34
MACD 0.04 -0.10
Stochastic Oscillator 26.49 18.66

Price Performance

Historical Comparison
AMPY
MGNX

About AMPY Amplify Energy Corp.

Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The companies oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana and Eagle Ford.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: